These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25213361)

  • 1. Progress of biological agents on psoriatic arthritis.
    Li Y; Wang D; Wang Y; Shi G
    Curr Pharm Biotechnol; 2014; 15(6):525-34. PubMed ID: 25213361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriatic arthritis: treatment strategies using biologic agents.
    D'Angelo S; Palazzi C; Olivieri I
    Reumatismo; 2012 Jun; 64(2):113-21. PubMed ID: 22690388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
    Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
    Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current concepts and new developments in the treatment of psoriatic arthritis.
    Pipitone N; Kingsley GH; Manzo A; Scott DL; Pitzalis C
    Rheumatology (Oxford); 2003 Oct; 42(10):1138-48. PubMed ID: 12810935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis.
    Graceffa D; Maiani E; Sperduti I; Ceralli F; Bonifati C
    Clin Exp Dermatol; 2015 Mar; 40(2):136-41. PubMed ID: 25438647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
    Salvarani C; Cantini F; Olivieri I
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S71-5. PubMed ID: 12463452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and investigational treatment of psoriatic arthritis.
    Prasad R; Gladman D
    Expert Opin Investig Drugs; 2004 Feb; 13(2):139-50. PubMed ID: 14996648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
    Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
    J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine profiles during infliximab monotherapy in psoriatic arthritis.
    Mastroianni A; Minutilli E; Mussi A; Bordignon V; Trento E; D'Agosto G; Cordiali-Fei P; Berardesca E
    Br J Dermatol; 2005 Sep; 153(3):531-6. PubMed ID: 16120138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin.
    Braun J; Sieper J
    BioDrugs; 2003; 17(3):187-99. PubMed ID: 12749755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review on golimumab in the treatment of psoriatic arthritis.
    Urdaneta M; Jethwa H; Sultan R; Abraham S
    Immunotherapy; 2017 Sep; 9(11):871-889. PubMed ID: 28838285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.
    Galadari H; Fuchs B; Lebwohl M
    Int J Dermatol; 2003 Mar; 42(3):231-7. PubMed ID: 12653923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature.
    Balsa A; Lula S; Marshall L; Szczypa P; Aikman L
    Expert Opin Biol Ther; 2018 May; 18(5):575-584. PubMed ID: 29533116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.